期刊
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
卷 16, 期 1, 页码 10-30出版社
WILEY
DOI: 10.1111/cts.13425
关键词
-
Global interest in CBD is increasing, with clinical trial evidence supporting high doses for treating childhood epilepsies. However, the therapeutic benefits of low-dose CBD products are still being debated. This review evaluated the efficacy and safety of low oral doses of CBD and found that doses of 300 mg or higher showed evidence of reducing anxiety and anti-addiction effects, but the effects on insomnia, neurological disorders, and chronic pain were limited and inconsistent.
Global interest in the non-intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity of health conditions. At present, there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10-50 mg/kg) in treating intractable childhood epilepsies. However, a question remains as to whether low-dose CBD products confer any therapeutic benefits. This is an important question to answer, as low-dose CBD products are widely available in many countries, often as nutraceutical formulations. The present review therefore evaluated the efficacy and safety of low oral doses of CBD. The review includes interventional studies that measured the clinical efficacy in any health condition and/or safety and tolerability of oral CBD dosed at less than or equal to 400 mg per day in adult populations (i.e., >= 18 years of age). Studies were excluded if the product administered had a Delta(9)-tetrahydrocannabinol content greater than 2.0%. Therapeutic benefits of CBD became more clearly evident at doses greater than or equal to 300 mg. Increased dosing from 60 to 400 mg/day did not appear to be associated with an increased frequency of adverse effects. At doses of 300-400 mg, there is evidence of efficacy with respect to reduced anxiety, as well as anti-addiction effects in drug-dependent individuals. More marginal and less consistent therapeutic effects on insomnia, neurological disorders, and chronic pain were also apparent. Larger more robust clinical trials are needed to confirm the therapeutic potential of lower (i.e., <300 mg/day) oral doses of CBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据